HAVCR2 and metastatic neoplasm: However, all Tcrd−/− mice treated with control isotype antibody (6 out of 6) succumbed to metastatic disease, whereas only 1 out of 5 Tcrd−/− mice treated with anti–PD-1 and 0 out of 6 Tcrd−/− mice treated with anti–TIM-3 developed lung metastases (Fig. 7 G).